U.S. patent application number 11/497124 was filed with the patent office on 2006-11-23 for methods to increase the capacity of high content cell-based screening assays.
This patent application is currently assigned to Cellomics, Inc.. Invention is credited to Megan Weiss, Joseph Zock.
Application Number | 20060265137 11/497124 |
Document ID | / |
Family ID | 23050344 |
Filed Date | 2006-11-23 |
United States Patent
Application |
20060265137 |
Kind Code |
A1 |
Zock; Joseph ; et
al. |
November 23, 2006 |
Methods to increase the capacity of high content cell-based
screening assays
Abstract
The present invention involves the pooling of multiple high
content cell-based screening assays, and carrying out a primary
screen in a one or more channels of a fluorescence detection
device, which drastically increases the number of simultaneous high
content cell-based screening events that can be carried out.
Subsequent deconvolution of primary screen "hits" (ie: those wells
or locations on an array of locations in which the one or more test
compounds caused a change in the fluorescence signal(s) from the
fluorescent reporter molecules in the cells) enables much more
rapid generation of high content cell screening data than was
previously possible, and at significantly reduced costs.
Inventors: |
Zock; Joseph; (Mars, PA)
; Weiss; Megan; (Pittsburgh, PA) |
Correspondence
Address: |
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO
IL
60606
US
|
Assignee: |
Cellomics, Inc.
|
Family ID: |
23050344 |
Appl. No.: |
11/497124 |
Filed: |
August 1, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10096378 |
Mar 12, 2002 |
7085765 |
|
|
11497124 |
Aug 1, 2006 |
|
|
|
60274969 |
Mar 12, 2001 |
|
|
|
Current U.S.
Class: |
702/19 |
Current CPC
Class: |
G01N 33/5076 20130101;
G01N 33/502 20130101; G01N 33/5008 20130101; G01N 33/5041 20130101;
G01N 33/582 20130101; G01N 33/5035 20130101; G01N 2500/20 20130101;
G01N 2500/10 20130101 |
Class at
Publication: |
702/019 |
International
Class: |
G06F 19/00 20060101
G06F019/00 |
Claims
1. A method for increasing the throughput of high content cell
based screening assays, comprising: a) providing at least a first
array of locations that contain multiple cells, wherein the cells
comprise a first reporter set, wherein the first reporter set
comprises at least a first fluorescent reporter molecule and a
second fluorescent reporter molecule, wherein the fluorescent
reporter molecules in the first reporter set i) report on different
cellular events; ii) exhibit phenotypically similar behavior; and
iii) emit fluorescence at wavelengths detectable in at least a
first channel of a fluorescence detection device; b) conducting a
primary screen that comprises imaging the at least first array of
locations in high content mode to obtain fluorescent signals in the
first channel from the fluorescent reporter molecules in the first
reporter set, wherein the imaging occurs either before, after,
and/or simultaneously with contacting of the at least first array
of locations with one or more test compounds; c) detecting test
compound induced changes in the fluorescent signals from the
fluorescent reporter molecules in the first reporter set, wherein a
test compound induced change in the fluorescent signals indicates
an effect of the one or more test compounds on one or more cellular
events reported on by the fluorescent reporter molecules in the
first reporter set; and d) deconvolving the test compound induced
changes, wherein the deconvolving comprises conducting one or more
secondary screens, wherein at least one of the secondary screens
comprises a method selected from the group consisting of: i)
screening positive locations on the first array of locations in
which test compound induced changes were detected in the primary
screen, and optionally screening one or more control locations on
the first array of locations, wherein the cells in the positive
locations and any control locations to be screened in the secondary
screen are further contacted with two or more further fluorescent
reporter molecules that are optically distinguishable from each
other and from the fluorescent reporter molecules in the first
reporter set, wherein at least one of the further fluorescent
reporter molecules reports on the same cellular event as the first
fluorescent reporter molecule, and wherein at least one of the
further fluorescent reporter molecules reports on the same cellular
event as the second fluorescent reporter molecule; and ii)
screening an at least second array of locations and an at least
third array of locations that contain multiple cells, wherein the
cells on the at least second array of locations comprise the first
fluorescent reporter molecule and not the second fluorescent
reporter molecule; and wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule; wherein
the deconvolving comprises contacting the at least second array of
locations and the at least third array of locations with only those
test compounds that produced test compound induced changes during
the primary screen, and optionally with one or more control
compounds.
2. The method of claim 1, wherein deconvolving comprises: A)
providing at least a second array of locations that contain
multiple cells, wherein the cells on the at least second array of
locations comprise the first fluorescent reporter molecule and not
the second fluorescent reporter molecule; B) providing at least a
third array of locations that contain multiple cells, wherein the
cells on the at least third array of locations comprise the second
fluorescent reporter molecule and not the first fluorescent
reporter molecule; C) imaging the at least second array of
locations and the at least third array of locations in high content
mode to obtain fluorescent signals from the first fluorescent
reporter molecule on the at least second array of locations and
fluorescent signals from the second fluorescent reporter molecule
on the at least third array of locations, wherein the imaging
occurs either before, after, and/or simultaneously with contacting
of the at least second array of locations and the at least third
array of locations with one or more active test compounds that
produced test compound induced changes during the primary screen,
and optionally with one or more control compounds; and D) detecting
active test compound induced changes in the fluorescent signals
from the first fluorescent reporter molecule on at least second
array of locations and/or the fluorescent signals from the second
fluorescent reporter molecule on the at least third array of
locations, wherein an active test compound induced change in the
fluorescent signals from the first fluorescent reporter molecule on
the at least second array of locations indicates an effect of the
one or more active test compounds on the cellular event reported on
by the first fluorescent reporter molecule, and wherein an active
test compound induced change in the fluorescent signals from the
second fluorescent reporter molecule on the at least third array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the second
fluorescent reporter molecule.
3. The method of claim 1, wherein deconvolving comprises A)
contacting the cells in only positive locations on the at least
first array of locations in which a test compound induced change
was detected, and optionally control locations, with at least a
third fluorescent reporter molecule and a fourth fluorescent
reporter molecule, wherein the third fluorescent reporter and the
fourth fluorescent molecule are optically distinguishable from each
other and from the first fluorescent reporter molecule and the
second fluorescent reporter molecule, and wherein the third
fluorescent reporter molecule reports on the same cellular event as
the first fluorescent reporter molecule, and wherein the fourth
fluorescent reporter molecule reports on the same cellular event as
the second fluorescent reporter molecule; B) imaging the positive
locations on the at least first array of locations, and optionally
control locations, in high content mode to obtain fluorescent
signals from the third fluorescent reporter molecule and the fourth
fluorescent reporter molecule; and C) detecting active test
compound induced changes in the fluorescent signals from the third
fluorescent reporter molecule and/or the fluorescent signals from
the fourth fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the third
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
first fluorescent reporter molecule, and wherein an active test
compound induced change in the fluorescent signals from the at
least fourth fluorescent reporter molecule indicates an effect of
the one or more active test compounds on the cellular event
reported on by the second fluorescent reporter molecule.
4. The method of claim 1, wherein the first reporter set further
comprises at least a third fluorescent reporter molecule.
5. The method of claim 4, wherein the deconvolving comprises
completely deconvolving the effect of the one or more test
compounds on each of the cellular events reported on by the
fluorescent reporter molecules in the first reporter set.
6. The method of claim 5, wherein completely deconvolving
comprises: A) providing at least a second array of locations that
contain multiple cells, wherein the cells on the at least second
array of locations comprise the first fluorescent reporter molecule
and not the second fluorescent reporter molecule or the third
fluorescent reporter molecule; B) providing at least a third array
of locations that contain multiple cells, wherein the cells on the
at least third array of locations comprise the second fluorescent
reporter molecule and not the first fluorescent reporter molecule
or the third fluorescent reporter molecule; C) providing at least a
fourth array of locations that contain multiple cells, wherein the
cells on the at least fourth array of locations comprise the third
fluorescent reporter molecule and not the first fluorescent
reporter molecule or the second fluorescent reporter molecule; D)
imaging the at least second array of locations, the at least third
array of locations, and the at least fourth array of locations in
high content mode to obtain fluorescent signals from the first
fluorescent reporter molecule on the at least second array of
locations, fluorescent signals from the second fluorescent reporter
molecule on the at least third array of locations, and fluorescent
signals from the third fluorescent reporter molecule on the at
least fourth array of locations, wherein the imaging occurs either
before, after, and/or simultaneously with contacting of the at
least second array of locations, the at least third array of
locations, and the at least fourth array of locations with one or
more active test compounds that produced test compound induced
changes during the primary screen, and optionally with one or more
controls; and E) detecting active test compound induced changes in
the fluorescent signals from the first fluorescent reporter
molecule on the at least second array of locations, the second
fluorescent reporter molecule on the at least third array of
locations, and/or the third fluorescent reporter molecule on the at
least fourth array of locations, wherein an active test compound
induced change in the fluorescent signals from the first
fluorescent reporter molecule on the at least second array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the first
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the second
fluorescent reporter molecule on the at least third array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the second
fluorescent reporter molecule, and wherein an active test compound
induced change in the fluorescent signals from the third
fluorescent reporter molecule on the at least fourth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the third
fluorescent reporter molecule.
7. The method of claim 5, wherein completely deconvolving comprises
A) contacting the cells in only positive locations on the at least
first array of locations in which a test compound induced change
was detected, and optionally control locations, with at least a
fourth fluorescent reporter molecule, a fifth fluorescent reporter
molecule, and a sixth fluorescent reporter molecule, wherein the
fourth fluorescent reporter molecule, the fifth fluorescent
reporter molecule, and the sixth fluorescent reporter molecule are
optically distinguishable from each other and from the fluorescent
reporter molecules in the first reporter set, and wherein the
fourth fluorescent reporter molecule reports on the same cellular
event as the first fluorescent reporter molecule, wherein the fifth
fluorescent reporter molecule reports on the same cellular event as
the second fluorescent reporter molecule, and wherein the sixth
fluorescent reporter molecule reports on the same cellular event as
the third fluorescent reporter molecule; B) imaging the positive
locations on the at least first array of locations, and optionally
control locations, in high content mode to obtain fluorescent
signals from the fourth fluorescent reporter molecule, the fifth
fluorescent reporter molecule, and the sixth fluorescent reporter
molecule; and C) detecting active test compound induced changes in
the fluorescent signals from the fourth fluorescent reporter
molecule, the fluorescent signals from the fifth fluorescent
reporter molecule, and/or the fluorescent signals from the sixth
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the fourth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
first fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the fifth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
second fluorescent reporter molecule, and wherein an active test
compound induced change in the fluorescent signals from the sixth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
third fluorescent reporter molecule.
8. The method of claim 4, wherein the deconvolving comprises
partially deconvolving the effect of the one or more active test
compounds on each of the cellular events reported on by the
fluorescent reporter molecules in the first reporter set.
9. The method of claim 8, wherein the partial deconvolving
comprises deconvolving the effect of the one or more active test
compounds on the cellular events reported on by less than all of
the fluorescent reporter molecules in the first reporter set.
10. The method of claim 9 wherein the partial deconvolving is done
on the at least first array of locations.
11. The method of claim 9 wherein the partial deconvolving is done
on an at least second array of locations.
12. The method of claim 1, wherein the cells further comprise at
least a second reporter set, wherein the at least second reporter
set comprises at least a third fluorescent reporter molecule and a
fourth fluorescent reporter molecule, wherein the fluorescent
reporter molecules in the second reporter set i) report on
different cellular events; ii) exhibit phenotypically similar
behavior; and iii) emit fluorescence at wavelengths detectable in
at least a second channel of a fluorescence detection device;
wherein the primary screen further comprises imaging the at least
first array of locations in high content mode to obtain fluorescent
signals in the second channel from the fluorescent reporter
molecules in the second reporter set; and wherein the detecting
further comprises detecting test compound induced changes in the
fluorescent signals from the fluorescent reporter molecules in the
second reporter set, wherein test compound induced changes in the
fluorescent signals from the fluorescent reporter molecules in the
second reporter set indicate an effect of the one or more test
compounds on one or more cellular events reported on by the at
least second reporter set.
13. The method of claim 12, wherein the deconvolving comprises
completely deconvolving the effect of the one or more test
compounds on the cellular events reported on by the first reporter
set and the cellular events reported on by the second reporter
set.
14. The method of claim 13, wherein completely deconvolving
comprises: A) providing at least a second array of locations that
contain multiple cells, wherein the cells on the at least second
array of locations comprise the first fluorescent reporter molecule
and not the second fluorescent reporter molecule, the third
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule; B) providing at least a third array of locations that
contain multiple cells, wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule, the third
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule; C) providing at least a fourth array of locations that
contain multiple cells, wherein the cells on the at least fourth
array of locations comprise the third fluorescent reporter molecule
and not the first fluorescent reporter molecule, the second
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule; D) providing at least a fifth array of locations that
contain multiple cells, wherein the cells on the at least fifth
array of locations comprise the fourth fluorescent reporter
molecule and not the first fluorescent reporter molecule, the
second fluorescent reporter molecule, or the third fluorescent
reporter molecule; E) imaging the at least second array of
locations, the at least third array of locations, the at least
fourth array of locations, and the at least fifth array of
locations in high content mode to obtain fluorescent signals from
the first fluorescent reporter molecule on the at least second
array of locations, fluorescent signals from the second fluorescent
reporter molecule on the at least third array of locations,
fluorescent signals from the third fluorescent reporter molecule on
the at least fourth array of locations, and fluorescent signals
from the fourth fluorescent reporter molecule on the at least fifth
array of locations, wherein the imaging occurs either before,
after, and/or simultaneously with contacting of the at least second
array of locations, the at least third array of locations, the at
least fourth array of locations, and the at least fifth array of
locations with one or more active test compounds that produced test
compound induced changes during the primary screen, and optionally
with one or more control compounds; and F) detecting active test
compound induced changes in the fluorescent signals from the first
fluorescent reporter molecule on the at least second array of
locations, the second fluorescent reporter molecule on the at least
third array of locations, the third fluorescent reporter molecule
on the at least fourth array of locations, and/or the fourth
fluorescent reporter molecule on the at least fifth array of
locations, wherein an active test compound induced change in the
fluorescent signals from the first fluorescent reporter molecule on
the at least second array of locations indicates an effect of the
one or more active test compounds on the cellular event reported on
by the first fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the second
fluorescent reporter molecule on the at least third array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the second
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the third
fluorescent reporter molecule on the at least fourth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the third
fluorescent reporter molecule, and wherein an active test compound
induced change in the fluorescent signals from the fourth
fluorescent reporter molecule on the at least fifth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the fourth
fluorescent reporter molecule.
15. The method of claim 13, wherein completely deconvolving
comprises A) contacting the cells in only positive locations on the
at least first array of locations in which a test compound induced
change was detected, and optionally control locations, with at
least a fifth fluorescent reporter molecule, a sixth fluorescent
reporter molecule, a seventh fluorescent reporter molecule, and an
eighth fluorescent reporter molecule, wherein the fifth fluorescent
reporter molecule, the sixth fluorescent molecule, the seventh
fluorescent molecule, and the eighth fluorescent molecule are
optically distinguishable from each other and from the fluorescent
reporter molecules in the first reporter set and the second
reporter set, and wherein the fifth fluorescent reporter molecule
reports on the same cellular event as the first fluorescent
reporter molecule, the sixth fluorescent molecule reports on the
same cellular event as the second fluorescent molecule, the seventh
fluorescent molecule reports on the same cellular event as the
third fluorescent molecule, and wherein the eighth fluorescent
reporter molecule reports on the same cellular event as the fourth
fluorescent reporter molecule; B) imaging the positive locations on
the at least first array of locations, and optionally control
locations, in high content mode to obtain fluorescent signals from
the fifth fluorescent reporter molecule, the sixth fluorescent
reporter molecule, the seventh fluorescent reporter molecule, and
the eighth fluorescent reporter molecule; and C) detecting active
test compound induced changes in the fluorescent signals from the
fifth fluorescent reporter molecule, the sixth fluorescent reporter
molecule, the seventh fluorescent reporter molecule, and/or the
eighth fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the fifth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
first fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the sixth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
second fluorescent reporter molecule, wherein an active test
compound induced change in the fluorescent signals from the seventh
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
third fluorescent reporter molecule, and wherein an active test
compound induced change in the fluorescent signals from the eighth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
fourth fluorescent reporter molecule.
16. The method of claim 12, wherein the deconvolving comprises
partially deconvolving the effect of the one or more test compounds
on the cellular events reported on by the first reporter set and
the cellular events reported on by the at least second reporter
set.
17. The method of claim 16, wherein the partial deconvolving
comprises deconvolving the effect of the one or more active test
compounds on the cellular events reported on by the fluorescent
reporter molecules in only one of the first reporter set and the at
least second reporter set.
18. The method of claim 16, wherein the partial deconvolving
comprises deconvolving the effect of the one or more active test
compounds on the cellular events reported on by less than all of
the fluorescent reporter molecules in one or both of the first
reporter set and the at least second reporter set.
19. The method of claim 17 wherein the partial deconvolving is done
on the at least first array of locations.
20. The method of claim 17 wherein the partial deconvolving is done
on an at least second array of locations.
21. The method of claim 18 wherein the partial deconvolving is done
on the at least first array of locations.
22. The method of claim 18 wherein the partial deconvolving is done
on an at least second array of locations.
Description
CROSS REFERENCE
[0001] This application claims priority to U.S. Provisional Patent
Application 60/274,969 filed Mar. 12, 2001.
FIELD OF THE INVENTION
[0002] The present invention related to the fields of drug
discovery, cell biology, and molecular biology.
BACKGROUND OF THE INVENTION
[0003] Drug discovery is a long, multiple step process involving
identification of specific disease targets, development of an assay
based on a specific target, validation of the assay, optimization
and automation of the assay to produce a screen, high throughput
screening of compound libraries using the assay to identify "hits",
hit validation, and hit compound optimization. The output of this
process is a lead compound that goes into pre-clinical studies and,
if validated, eventually into clinical trials. In this process, the
screening phase is distinct from the assay development phases, and
involves testing compound efficacy in living biological
systems.
[0004] Historically, drug discovery is a slow and costly process,
spanning numerous years and consuming hundreds of millions of
dollars per drug created. Developments in the areas of genomics,
proteomics, and high throughput screening have resulted in
increased capacity and efficiency in the areas of target
identification, structure-function predictions, and volume of
compounds screened. Significant advances in automated DNA
sequencing, PCR application, positional cloning, hybridization
arrays, and bioinformatics have greatly increased the number of
genes (and gene fragments) encoding potential drug screening
targets. However, the basic scheme for drug screening remains the
same.
[0005] The next level of biological complexity is the cell, and
sophisticated automated methods for cell-based screening based on
imaging of fluorescent reporter molecules in cells have recently
been developed. (See, for example, U.S. Pat. Nos. 5,989,835 and
6,103,479, as well as published PCT application nos. WO 98/38490,
WO 00/03246, WO 00/17643, WO 00/26408, WO 00/50872, WO/00/70342, WO
00/17624, and WO/00/60356.) The process of implementing such
cell-based assays is also referred to as high content screening
("HCS"), and addresses a need for more detailed information about
the temporal-spatial dynamics of cell constituents and processes,
and how they are affected by potential drug candidates.
[0006] HCS automates the extraction of multicolor luminescence
information derived from specific luminescence-based reagents
incorporated into cells (Giuliano and Taylor (1995), Curr. Op. Cell
Biol. 7:4; Giuliano et al. (1995) Ann. Rev. Biophys. Biomol.
Struct. 24:405). Cells are analyzed using an optical system that
can measure spatial, as well as temporal dynamics. (Farkas et al.
(1993) Ann. Rev. Physiol. 55:785; Giuliano et al. (1990) In Optical
Microscopy for Biology. B. Herman and K. Jacobson (eds.), pp.
543-557. Wiley-Liss, New York; Hahn et al (1992) Nature 359:736;
Waggoner et al. (1996) Hum. Pathol. 27:494). The concept is to
treat each cell as a "well" that has spatial and temporal
information on the activities of the labeled constituents.
[0007] HCS can be performed on living or fixed cells, using a
variety of labeled reporter molecules, such as antibodies,
biological ligands, nucleic acid hybridization probes, and
multicolor luminescent indicators and "biosensors." The choice of
fixed or live cell screens depends on the specific cell-based assay
required.
[0008] The results obtained from HCS provide more relevant
information about a drug candidate's potential effect on cells than
is available from genomic or proteomic methods, and can
dramatically reduce costs in animal testing, while increasing the
speed of new drug development.
[0009] While HCS can be combined on a single platform with high
throughput screening (HTS) (see, for example, U.S. Pat. Nos.
5,989,835 and 6,103,479, as well as published PCT application no.
WO 98/38490), methods that further increase the throughput
capabilities of high content cell-based drug screening would be of
great value to the art. The average "hit" rate (i.e.: detection of
a positive response) in most viable high content cell-based screens
ranges from 0.1% to 1.0% of compounds screened. Therefore, the vast
majority of wells screened in a microplate format yield a negative
response, necessitating the screening of a large number of wells to
detect a response of interest, which significantly impacts the
capacity requirements of such high content cell-based screening
assays. Thus, methods that increase the capacity to provide high
content information on the effect of a test compound on cellular
events of interest, while maintaining the "hit" rate, would provide
a tremendous increase in the utility of high content cell based
screens.
SUMMARY OF THE INVENTION
[0010] The present invention fulfills the need in the art for
methods to increase the capacity to provide high content
information on the effect of a test compound on cellular events of
interest, while maintaining the "hit" rate, and dramatically reduce
the cost and time required to carry out high content cell-based
screening, and is further applicable to methods for high throughput
screening of a variety of biological targets.
[0011] In one aspect, methods are provided for increasing the
throughput of high content cell based screening assays,
comprising:
[0012] a) providing at least a first array of locations that
contain multiple cells, wherein the cells comprise a first reporter
set, wherein the first reporter set comprises at least a first
fluorescent reporter molecule and a second fluorescent reporter
molecule, wherein the fluorescent reporter molecules in the first
reporter set [0013] i) report on different cellular events; [0014]
ii) exhibit phenotypically similar behavior; and [0015] iii) emit
fluorescence at wavelengths detectable in at least a first channel
of a fluorescence detection device;
[0016] b) conducting a primary screen that comprises imaging the at
least first array of locations in high content mode to obtain
fluorescent signals in the first channel from the fluorescent
reporter molecules in the first reporter set, wherein the imaging
occurs either before, after, and/or simultaneously with contacting
of the at least first array of locations with one or more test
compounds;
[0017] c) detecting test compound induced changes in the
fluorescent signals from the fluorescent reporter molecules in the
first reporter set, wherein a test compound induced change in the
fluorescent signals indicates an effect of the one or more test
compounds on one or more cellular event(s) reported on by the
fluorescent reporter molecules in the first reporter set; and
[0018] d) deconvolving the test compound induced changes, wherein
the deconvolving comprises conducting one or more secondary
screens.
[0019] In a preferred embodiment, at least one of the secondary
screens comprises a method selected from the group consisting of:
[0020] i) screening positive locations on the first array of
locations in which test compound induced changes were detected in
the primary screen, and optionally screening one or more control
locations on the first array of locations, wherein the cells in the
positive locations and any control locations to be screened in the
secondary screen are further contacted with two or more further
fluorescent reporter molecules that are optically distinguishable
from each other and from the fluorescent reporter molecules in the
first reporter set, wherein at least one of the further fluorescent
reporter molecules reports on the same cellular event as the first
fluorescent reporter molecule, and wherein at least one of the
further fluorescent reporter molecules reports on the same cellular
event as the second fluorescent reporter molecule; and [0021] ii)
screening an at least second array of locations and an at least
third array of locations that contain multiple cells, wherein the
cells on the at least second array of locations comprise the first
fluorescent reporter molecule and not the second fluorescent
reporter molecule; and wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule; wherein
the deconvolving comprises contacting the at least second array of
locations and the at least third array of locations with only those
test compounds that produced test compound induced changes during
the primary screen, and optionally with one or more control
compounds.
[0022] In a further embodiment, the first reporter set comprises
three or more fluorescent reporter molecules. In this embodiment,
deconvolving can comprise either partially or completely
deconvolving the effect of the one or more test compounds on the
cellular events reported on by the fluorescent reporter molecules
in the first reporter set.
[0023] In another embodiment, the cells further comprise at least a
second reporter set, wherein the at least second reporter set
comprises at least a third fluorescent reporter molecule and a
fourth fluorescent reporter molecule, wherein the fluorescent
reporter molecules in the second reporter set [0024] i) report on
different cellular events; [0025] ii) exhibit phenotypically
similar behavior; and [0026] iii) emit fluorescence at wavelengths
detectable in at least a second channel of a fluorescence detection
device;
[0027] wherein the primary screen further comprises imaging the at
least first array of locations in high content mode to obtain
fluorescent signals in the second channel from the fluorescent
reporter molecules in the second reporter set; and
[0028] wherein the detecting further comprises detecting test
compound induced changes in the fluorescent signals from the
fluorescent reporter molecules in the second reporter set, wherein
test compound induced changes in the fluorescent signals from the
fluorescent reporter molecules in the second reporter set indicate
an effect of the one or more test compounds on one or more cellular
events reported on by the at least second reporter set.
[0029] In this embodiment, deconvolving can comprise either
partially or completely deconvolving the effect of the one or more
test compounds on the cellular events reported on by the
fluorescent reporter molecules in the first reporter set and the
second reporter set.
BRIEF DESCRIPTION OF THE FIGURES
[0030] FIG. 1 is a schematic example of results obtained when using
a single reporter set with four fluorescent reporter molecules, and
deconvolving on a separate array of locations.
[0031] FIG. 2 is a schematic example of results obtained when using
two reporter sets with two fluorescent reporter molecules in each
reporter set, and deconvolving on a separate array of
locations.
[0032] FIG. 3 is a schematic example of results obtained when using
a single reporter set with 3 fluorescent reporter molecules, and
partially deconvolving on the same array of locations as was used
for the primary screen.
[0033] FIG. 4 is a schematic demonstration of potential timesaving,
relative to standard high content cell-based screening, of an
embodiment of the methods of the invention wherein the cells
comprise a single reporter set consisting of 4 fluorescent reporter
molecules.
[0034] FIG. 5 is a bar graph demonstrating that both NFkB and ERK
specific translocations can be observed in response to TNF and PMA
in the green channel, while anisomysin has no effect on
translocation in the green channel over negative controls.
[0035] FIG. 6 is a bar graph demonstrating an increase in
translocation for p38 and c-jun in response to PMA and anisomysin
but not TNF in the red channel.
DETAILED DESCRIPTION OF THE INVENTION
[0036] The present invention involves the pooling of multiple high
content cell-based screening assays, and carrying out a primary
screen in one or more channels of a fluorescence detection device,
which drastically increases the number of simultaneous high content
cell-based screening events that can be carried out. Subsequent
deconvolution of primary screen "hits" (ie: those wells or
locations on an array of locations in which the one or more test
compounds caused a change in the fluorescence signal(s) from the
fluorescent reporter molecules in the cells) enables much more
rapid generation of high content cell screening data than was
previously possible, and at significantly reduced costs.
[0037] In one aspect, the present invention provides methods for
increasing the throughput of high content cell based screening
assays, comprising:
[0038] a) providing at least a first array of locations that
contain multiple cells, wherein the cells comprise a first reporter
set, wherein the first reporter set comprises at least a first
fluorescent reporter molecule and a second fluorescent reporter
molecule, wherein the fluorescent reporter molecules in the first
reporter set [0039] i) report on different cellular events; [0040]
ii) exhibit phenotypically similar behavior; and [0041] iii) emit
fluorescence at wavelengths detectable in at least a first channel
of a fluorescence detection device;
[0042] b) conducting a primary screen that comprises imaging the at
least first array of locations in high content mode to obtain
fluorescent signals in the first channel from the fluorescent
reporter molecules in the first reporter set, wherein the imaging
occurs either before, after, and/or simultaneously with contacting
of the at least first array of locations with one or more test
compounds;
[0043] c) detecting test compound induced changes in the
fluorescent signals from the fluorescent reporter molecules in the
first reporter set, wherein a test compound induced change in the
fluorescent signals indicates an effect of the one or more test
compounds on one or more cellular event(s) reported on by the
fluorescent reporter molecules in the first reporter set; and
[0044] d) deconvolving the test compound induced changes, wherein
the deconvolving comprises conducting one or more secondary
screens.
[0045] In a preferred embodiment, at least one of the secondary
screens comprises a method selected from the group consisting of:
[0046] i) screening positive locations on the first array of
locations in which test compound induced changes were detected in
the primary screen, and optionally screening one or more control
locations on the first array of locations, wherein the cells in the
positive locations and any control locations to be screened in the
secondary screen are further contacted with two or more further
fluorescent reporter molecules that are optically distinguishable
from each other and from the fluorescent reporter molecules in the
first reporter set, wherein at least one of the further fluorescent
reporter molecules reports on the same cellular event as the first
fluorescent reporter molecule, and wherein at least one of the
further fluorescent reporter molecules reports on the same cellular
event as the second fluorescent reporter molecule; and [0047] ii)
screening an at least second array of locations and an at least
third array of locations that contain multiple cells, wherein the
cells on the at least second array of locations comprise the first
fluorescent reporter molecule and not the second fluorescent
reporter molecule; and wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule; wherein
the deconvolving comprises contacting the at least second array of
locations and the at least third array of locations with only those
test compounds that produced test compound induced changes during
the primary screen, and optionally with one or more control
compounds.
[0048] The use of deconvolution greatly decreases the time and
expense of simultaneously identifying the effect of a given test
compound or compounds on a number of different cellular events.
[0049] As used herein, an "array" includes any substrate, or
portion of such a substrate, on which multiple locations of cells
can be attached, including but not limited to microplates with any
number of wells, slides, chambered slides, chemically or physically
patterned substrates, and microwells on a microplate, as described
in U.S. Pat. No. 6,103,479, incorporated by reference herein in its
entirety. Thus, an array of locations could, for example, be a 96
well microplate, as is standard in the art; it could also be some
subsection of a 96 well microplate, such as 1, 4, 8, 16, 32, or 48
wells on a 96 well microplate. Thus, in embodiments of the
invention when more than one array of locations are used,
recitation of a "second array of locations," etc., encompasses both
the situation where the first and second array of locations (or
second and third array of locations, etc.) are on different
substrates, such as two separate microplates, and also encompasses
the situation wherein the first array of locations is a one portion
of a substrate, such as a microplate, while the second array of
locations is a separate portion of the same microplate.
[0050] As used herein, the cells on an "array of locations" can
comprise a homogenous population of cells with respect to reporter
set, or can comprise multiple cell populations, wherein each cell
population comprises a different reporter set, in order to further
increase the capability of the high content screen.
[0051] As used herein, "control locations" can be locations without
cells (for example, media plus one or more test compounds only), or
locations with cells that have been treated in such a way as to
provide a control for the interpretation of the assay results (for
example, cells not treated with any test compound; cells treated
with a control compound of some sort (such as a known activator or
inhibitor of the cellular event being assayed), etc.).
[0052] As used herein, the phrase "the cells comprise a first
reporter set" means that individual fluorescent reporter molecules
may be expressed by transfected cells or added to the cells via
non-mechanical modes including, but not limited to, diffusion,
facilitated or active transport, signal-sequence-mediated
transport, and endocytotic or pinocytotic uptake; or combinations
thereof, at any time during the screening assay. Mechanical bulk
loading methods, which are well known in the art, can also be used
to load fluorescent probes into living cells (Barber et al. (1996),
Neuroscience Letters 207:17-20; Bright et al. (1996), Cytometry
24:226-233; McNeil (1989) in Methods in Cell Biology, Vol. 29,
Taylor and Wang (eds.), pp. 153-173). These methods include, but
are not limited to, electroporation and other mechanical methods
such as scrape-loading, bead-loading, impact-loading,
syringe-loading, hypertonic and hypotonic loading. Additionally,
cells can be genetically engineered to express fluorescent reporter
molecules, such as green fluorescent protein (GFP), coupled to a
protein of interest (Chalfie and Prasher U.S. Pat. No. 5,491,084;
Cubitt et al. (1995), Trends in Biochemical Science 20:448-455).
Fluorescently labeled antibodies are particularly useful reporter
molecules, due to their high degree of specificity for attaching to
a single molecular target in a mixture of molecules as complex as a
cell. The fluorescent reporter molecules that a given cell
possesses may all be introduced to the cells via the same
technique, or via any combination of such techniques.
[0053] There is a continually growing family of fluorescent
reagents that are used to measure the temporal and spatial
distribution, content, and activity of intracellular ions,
metabolites, macromolecules, and organelles. Classes of these
fluorescent reporter molecules include, but are not limited to,
fluorescently labeled biomolecules, such as proteins,
phospholipids, nucleic acid hybridizing probes, antibodies, and
small molecules. Once in the cell, the fluorescent reporter
molecules accumulate at their target domain as a result of specific
and high affinity interactions with the target domain (either
directly or indirectly, through another molecule) or other modes of
molecular targeting such as signal-sequence-mediated transport.
[0054] As used herein, "changes" in the fluorescent signals that
are detected include, but are not limited to, the broad classes of
changes in fluorescence intensity, changes in fluorescence spatial
distribution, and spectral shifting. Changes in fluorescence
intensity include, but are not limited to, increase or decrease of
fluorescence intensity, and changes in the ratio of fluorescence
intensity relative to a control sample, a different cellular
compartment, or relative to the same cell at different time points.
Changes in fluorescence spatial distribution include any
redistribution in the cell, or changes in distribution ratios of
the fluorescent reporter molecules, either between different
cellular compartments in the same cell at different time points, or
relative to a control sample. "Spectral shifting" means a change in
the fluorescence emission profile of a fluorescent reporter
molecule including but not limited to changes occurring as a result
of fluorescent resonance energy transfer (FRET) and fluorescence
lifetime measurements (FLM).
[0055] As used herein, the term "reporter set" means two or more
fluorescent reporter molecules that [0056] i) report on different
cellular events; [0057] ii) exhibit phenotypically similar
behavior; and [0058] iii) emit fluorescence at wavelengths
detectable in at least a first channel of a fluorescence detection
device.
[0059] As used herein, the term "cellular event" means a cellular
response that can be reported on by a detectable reporter molecule,
such as a fluorescent reporter molecule. Non-limiting examples of
such cellular responses include, but are not limited to,
translocation of a cellular factor (including, but not limited to,
proteins, nucleic acids, and lipids) between one part of the cell
and another (including, but not limited to, between organelles and
other specialized cell structures, such as between
cytoplasm-nucleus, cytoplasm-cell membrane, cell membrane-nucleus,
endoplasmic reticulum-golgi, organelles and cellular polymeric
networks, such as microtubules, intermediate filaments, and actin
filaments, etc.), changes in the mass of a cell structure
(including but not limited to organelles, polymeric networks, such
as microtubules, intermediate filaments, and actin filaments),
changes in the structural characteristics of a cell structure
(including but not limited to changes in the degree of
polymerization of a cell structure; changes in the integrity of a
cell structure, etc.), changes in the activity of a cellular factor
(including but not limited to enzymatic activation, expression, and
other modifications), and changes in environment of a reporter
molecule (including, but not limited to, changes in pH environment,
ionic environment (Ca.sup.++, K.sup.+, Na.sup.+, etc.), and lipid
environment). The fluorescent reporter molecule can directly report
on the cellular event (for example, a primary antibody binding to a
transcription factor that is being assayed for translocation from
the cytoplasm to the nucleus), or may indirectly report on the
cellular event (for example, a secondary antibody binding to the
antibody binding to a transcription factor that is being assayed
for translocation from the cytoplasm to the nucleus).
[0060] "Different" cellular events refer to non-identical events.
Thus, two fluorescent reporter molecules that each report on
translocation of c-jun from the cytoplasm to the nucleus do not
report on "different cellular events", while if one fluorescent
reporter molecule reports on c-jun translocation from the cytoplasm
to the nucleus, while a second fluorescent reporter molecule
reports on translocation of c-fos from the cytoplasm to the
nucleus, then the two reporters report on different cellular
events. Alternatively, the second fluorescent reporter molecule may
report on viral infection, so long as it and the first fluorescent
reporter molecule exhibit phenotypically similar behavior in the
cell, as defined below. Thus, more than one specific cellular event
is being reported on by each reporter set, providing for parallel
analysis of multiple cellular events in a single primary screen. As
discussed further below, the cells may comprise more than one
reporter set, and each reporter set may comprise any number of such
different fluorescent reporter molecules, so long as they fulfill
the further requirements set out below.
[0061] That two or more fluorescent reporter molecules in a single
reporter set exhibit "phenotypically similar behavior" in the cell
means that the two or more fluorescent reporter molecules occupy a
similar space in the cell (for example, they are each predominately
non-nuclear and cytoplasmic) and move in a similar way in the cell
(for example, upon activation they predominately move to the
nucleus), so that they can be analyzed simultaneously by an
appropriate image analysis method. For example, a first fluorescent
reporter molecule reports on c-jun activation by translocating from
the cytoplasm to the nucleus upon activation, while a second
fluorescent reporter molecule reports on viral infection by
translocating from the cytoplasm to the nucleus upon viral
infection. Since both fluorescent reporter molecules move from the
cytoplasm to the nucleus upon appropriate stimulation, they exhibit
"phenotypically similar behavior", and can be simultaneously
analyzed by an image analysis method that measures translocation of
a fluorescent reporter molecule between the cytoplasm and nucleus
of the cells. One of skill in the art will recognize that similar
reporter sets of phenotypically similar fluorescent reporter
molecules (including those with more than two fluorescent reporter
molecules) can be designed for any type of translocation, mass
detection, structural characteristic detection, and environment
sensing, as discussed in more detail below.
[0062] As used herein, "emit fluorescence at wavelengths detectable
in at least a first channel of a fluorescence detection device"
means that the different fluorescent reporter molecules in the
first reporter set emit fluorescence within the wavelength cut-off
range of the filter set used to collect fluorescence for a
particular channel. One or more of the reporters in a single
reporter set may also emit fluorescence outside the wavelength
cut-off range, so long as it does significantly not bleed through
(contaminate) other channels that are also being used to measure
fluorescence either from fluorescent reporter molecules in other
reporter sets, or from other fluorescence reporters used to
deconvolve the results of the primary screen or to identify
specific cellular structures for the purposes of specific high
content screening assays (such as the use of a nuclear stain to
identify individual cells, when so desired). This phrase does not
mean that the fluorescent reporter molecules in the first reporter
set do not emit fluorescence outside of the first channel
cut-off.
[0063] In another embodiment, the cells further comprise at least a
second reporter set, wherein the at least second reporter set
comprises at least a third fluorescent reporter molecule and a
fourth fluorescent reporter molecule, wherein the fluorescent
reporter molecules in the second reporter set [0064] i) report on
different cellular events; [0065] ii) exhibit phenotypically
similar behavior; and [0066] iii) emit fluorescence at wavelengths
detectable in at least a second channel of a fluorescence detection
device;
[0067] wherein the primary screen further comprises imaging the at
least first array of locations in high content mode to obtain
fluorescent signals in the second channel from the fluorescent
reporter molecules in the second reporter set; and
[0068] wherein the detecting further comprises detecting test
compound induced changes in the fluorescent signals from the
fluorescent reporter molecules in the second reporter set, wherein
test compound induced changes in the fluorescent signals from the
fluorescent reporter molecules in the second reporter set indicate
an effect of the one or more test compounds on one or more cellular
event(s) reported on by the at least second reporter set.
[0069] Thus, when multiple reporter sets are used, each reporter
set is imaged in a different channel of the fluorescence detection
device. Thus, the fluorescent reporter molecules in the first
reporter set must be "optically distinguishable" from the
fluorescent reporter molecules in the second reporter set. As used
herein, "optically distinguishable" or "spectrally distinguishable"
means that fluorescent signals from more than one fluorescent
reporter molecule are distinguishable from each other. Preferably,
the optically distinguishable reporter molecules do not emit
fluorescence at overlapping wavelengths. However, where a first
fluorescent reporter molecule has overlapping wavelengths of
fluorescence emission with a second fluorescent reporter molecule,
such overlapping is acceptable, so long as the fluorescent signals
from the first fluorescent reporter molecule do not obscure the
detectable signals from the second fluorescent reporter molecule in
the channel for detecting fluorescence emission from the second
fluorescent reporter molecule.
[0070] In a preferred embodiment, each reporter set emits
fluorescence at wavelengths not detectable in the channel used to
image the fluorescent signals from the other reporter set. Any
number of different reporter sets can be used in the methods of the
present invention, so long as the fluorescence emission from the
different sets can be imaged in separate, non-overlapping channels
as described above.
[0071] In a preferred embodiment, reporter sets are designed to
analyze several parts of a cellular pathway with the same reporter
set, so that a "hit" could identify a pathway affected by the test
compound, and deconvolution can be used to identify the step in the
pathway that the test compound affected.
[0072] As used herein, "imaging in high content mode" means
detection of fluorescence signals at subcellular resolution,
wherein the cellular localization of the fluorescence signals is
determined. Such a high content mode image comprises a digital
representation of the fluorescent signals from the fluorescent
reporter molecules, and does not require a specific arrangement or
display of the digital representation. In preferred embodiments,
well known formats for such "images" are employed, including but
not limited to .dib, .tiff, .jpg, .bmp. In further preferred
embodiments, the images are analyzed algorithmically, and/or
displayed to provide a visual representation of the image.
[0073] The one or more test compounds can be of any nature,
including, but not limited to, chemical and biological compounds
and environmental samples. The one or more test compounds may also
comprise a plurality of compounds, including but not limited to
combinatorial chemical libraries and natural compound libraries.
Contacting of the cells with the one or more test compounds can
occur before, after, and/or simultaneously with imaging of the
cells, depending on the assay design. For example, in order to
carry out kinetic screening, it is necessary to image the cells at
multiple time points, and the user may acquire such images before,
at the time of, and after contacting of the cells with the test
compound.
[0074] As used herein, the term "primary screen" refers to the
screen in which the cumulative response to the test compound of all
of the fluorescent reporter molecules in the reporter sets are
determined, with no distinction being made as to the relative
contribution of any of the individual fluorescent reporter molecule
responses.
[0075] Thus, the cumulative effect of the one or more test
compounds on all of the fluorescent reporter molecules in the
reporter sets is determined in the primary screen. In some cases,
no further screening is necessary. For example, such information is
particularly useful where it is desired to determine if a test
compound produces a given phenotypic event, but it is not necessary
to identify the specific cellular event that the test compound acts
on. In one non-limiting example, if it was desired to identify a
test compound that affected a specific cell signaling pathway, then
one could design a reporter set consisting of three fluorescent
reporter molecules that reported on activation of three different
transcription factors in the specific cell signaling pathway,
wherein activation of the signaling pathway induced translocation
of one or more of the transcription factors to the nucleus from the
cytoplasm. Upon contact with an activating test compound, the array
of locations would be imaged to identify translocation of
fluorescent signals from the cytoplasm to the nucleus, and an
activator of the specific cell signaling pathway would thus be
identified.
[0076] As used herein, the term "deconvolve" or "deconvolving"
means performing one or more secondary assays to determine which of
the individual fluorescent reporter molecules in a reporter set
were affected by the one or more test compounds that produced an
effect in the primary screen (the "active test compound(s)").
Deconvolving can be carried out on the same array of locations as
the primary screen, or can be carried out on one or more array(s)
of locations other than the at least first array of locations on
which the primary screen was conducted. In either case, control
locations and control test compounds can optionally be
employed.
[0077] When individual wells on the at least first array of
locations are contacted with more than one test compound,
deconvolving can also comprise a two dimensional deconvolution,
comprising deconvolving the effects of each individual test
compound used to contact positive locations on the primary screen,
as well as determining which of the individual fluorescent reporter
molecules in a reporter set were affected by the test compounds in
the primary screen.
[0078] If deconvolving is carried out on fixed cells and on the
same array of locations as the primary screen, then it is not
required to contact the cells again with the one or more test
compounds that were active in the primary screen. If deconvolving
is carried out on live cells and on the same array of locations as
the primary screen, then it may be necessary to contact the cells
again with the one or more test compounds that were active in the
primary screen, depending on the amount of time elapsed between the
primary screen and the secondary screen(s), as well as the duration
of the response assayed in the primary screen. If deconvolving is
carried out on a different array of locations than the primary
screen, it is necessary to contact the cells to be screened in the
secondary screen(s) with the one or more test compounds that were
active in the primary screen.
[0079] Deconvolution can be carried out in many ways, including but
not limited to:
[0080] 1. Complete deconvolution completely separates the effect of
the one or more test compounds on each of the cellular events
reported on by the fluorescent reporter molecules in the primary
screen. [0081] a. All secondary screens carried out on new arrays
of locations: A separate array of locations containing cells is
provided for each fluorescent reporter molecule in a reporter set,
wherein the cells in each individual array of locations possesses
only one of the fluorescent reporter molecules from a given
reporter set. For example, if in the primary screen the cells
possess three fluorescent reporter molecules (A, B, and C) in a
single reporter set, then in the secondary screen, three different
arrays of locations (1, 2, and 3) are used, each array of locations
containing cells with only one of the reporters (For example, cells
on array of locations 1 possess reporter A, cells on array of
locations 2 possess reporter B, and cells on array of locations 3
possess reporter C). Thus, a different secondary screen is
conducted, and different images are obtained, for each fluorescent
reporter molecule, with all screens being carried out on different
arrays of locations than the one on which the primary screen was
conducted.
[0082] For example, one embodiment of complete deconvolving using
all secondary screens carried out on separate arrays of locations
from the primary screen, when the cells possess a single reporter
set of two fluorescent reporter molecules, comprises:
[0083] A) providing at least a second array of locations that
contain multiple cells, wherein the cells on the at least second
array of locations comprise the first fluorescent reporter molecule
and not the second fluorescent reporter molecule;
[0084] B) providing at least a third array of locations that
contain multiple cells, wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule;
[0085] C) imaging the at least second array of locations and the at
least third array of locations in high content mode to obtain
fluorescent signals from the first fluorescent reporter molecule on
the at least second array of locations and fluorescent signals from
the second fluorescent reporter molecule on the at least third
array of locations, wherein the imaging occurs either before,
after, and/or simultaneously with contacting of the at least second
array of locations and the at least third array of locations with
one or more active test compounds that produced test compound
induced changes during the primary screen, and optionally with one
or more control compounds; and
[0086] D) detecting active test compound induced changes in the
fluorescent signals from the first fluorescent reporter molecule on
at least second array of locations and/or the fluorescent signals
from the second fluorescent reporter molecule on the at least third
array of locations, wherein an active test compound induced change
in the fluorescent signals from the first fluorescent reporter
molecule on the at least second array of locations indicates an
effect of the one or more active test compounds on the cellular
event reported on by the first fluorescent reporter molecule, and
wherein an active test compound induced change in the fluorescent
signals from the second fluorescent reporter molecule on the at
least third array of locations indicates an effect of the one or
more active test compounds on the cellular event reported on by the
second fluorescent reporter molecule.
[0087] If the cells possess a single reporter set of three
different fluorescent reporter molecules, one embodiment of
complete deconvolution on new arrays of locations comprises:
[0088] A) providing at least a second array of locations that
contain multiple cells, wherein the cells on the at least second
array of locations comprise the first fluorescent reporter molecule
and not the second fluorescent reporter molecule or the third
fluorescent reporter molecule;
[0089] B) providing at least a third array of locations that
contain multiple cells, wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule or the
third fluorescent reporter molecule;
[0090] C) providing at least a fourth array of locations that
contain multiple cells, wherein the cells on the at least fourth
array of locations comprise the third fluorescent reporter molecule
and not the first fluorescent reporter molecule or the second
fluorescent reporter molecule;
[0091] D) imaging the at least second array of locations, the at
least third array of locations, and the at least fourth array of
locations in high content mode to obtain fluorescent signals from
the first fluorescent reporter molecule on the at least second
array of locations, fluorescent signals from the second fluorescent
reporter molecule on the at least third array of locations, and
fluorescent signals from the third fluorescent reporter molecule on
the at least fourth array of locations, wherein the imaging occurs
either before, after, and/or simultaneously with contacting of the
at least second array of locations, the at least third array of
locations, and the at least fourth array of locations with one or
more active test compounds that produced test compound induced
changes during the primary screen, and optionally with one or more
controls; and
[0092] E) detecting active test compound induced changes in the
fluorescent signals from the first fluorescent reporter molecule on
the at least second array of locations, the second fluorescent
reporter molecule on the at least third array of locations, and/or
the third fluorescent reporter molecule on the at least fourth
array of locations, wherein an active test compound induced change
in the fluorescent signals from the first fluorescent reporter
molecule on the at least second array of locations indicates an
effect of the one or more active test compounds on the cellular
event reported on by the first fluorescent reporter molecule,
wherein an active test compound induced change in the fluorescent
signals from the second fluorescent reporter molecule on the at
least third array of locations indicates an effect of the one or
more active test compounds on the cellular event reported on by the
second fluorescent reporter molecule, and wherein an active test
compound induced change in the fluorescent signals from the third
fluorescent reporter molecule on the at least fourth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the third
fluorescent reporter molecule.
[0093] An example of complete deconvolution on a separate array of
locations when the cells comprise a single reporter set of 4
fluorescent reporter molecules (F1-F4) is shown in FIG. 1. The
primary screen is conducted in this example on a 96 well plate (the
first array of locations), with a hit at location D4. The test
compound or compounds used at location D4 in the primary screen
is/are then used to screen separate arrays of locations, wherein
the cells in any location comprise only one of F1-F4 (or none, such
as in optional control wells). The cells in each well are different
with respect to fluorescent reporter molecule, and thus each well
constitutes a separate "array of locations". In this example, four
separate arrays of locations are used, wherein each array of
locations consists of a single well, and each array of locations is
on a single microplate. If the primary screen had yielded two hits,
then the secondary screening would have involved 2 different wells
for each cell type (ie: two F1 wells, each with one of the two
compounds that were identified as hits, etc.) In this case, there
would still have been four arrays of locations, with each array
consisting of two wells (e.g.: the two F1 wells make up a second
array of locations, etc.)
[0094] If the cells possess two reporter sets of two different
fluorescent reporter molecules, one embodiment of complete
deconvolution on new arrays of locations comprises:
[0095] A) providing at least a second array of locations that
contain multiple cells, wherein the cells on the at least second
array of locations comprise the first fluorescent reporter molecule
and not the second fluorescent reporter molecule, the third
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule;
[0096] B) providing at least a third array of locations that
contain multiple cells, wherein the cells on the at least third
array of locations comprise the second fluorescent reporter
molecule and not the first fluorescent reporter molecule, the third
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule;
[0097] C) providing at least a fourth array of locations that
contain multiple cells, wherein the cells on the at least fourth
array of locations comprise the third fluorescent reporter molecule
and not the first fluorescent reporter molecule, the second
fluorescent reporter molecule, or the fourth fluorescent reporter
molecule;
[0098] D) providing at least a fifth array of locations that
contain multiple cells, wherein the cells on the at least fifth
array of locations comprise the fourth fluorescent reporter
molecule and not the first fluorescent reporter molecule, the
second fluorescent reporter molecule, or the third fluorescent
reporter molecule;
[0099] E) imaging the at least second array of locations, the at
least third array of locations, the at least fourth array of
locations, and the at least fifth array of locations in high
content mode to obtain fluorescent signals from the first
fluorescent reporter molecule on the at least second array of
locations, fluorescent signals from the second fluorescent reporter
molecule on the at least third array of locations, fluorescent
signals from the third fluorescent reporter molecule on the at
least fourth array of locations, and fluorescent signals from the
fourth fluorescent reporter molecule on the at least fifth array of
locations, wherein the imaging occurs either before, after, and/or
simultaneously with contacting of the at least second array of
locations, the at least third array of locations, the at least
fourth array of locations, and the at least fifth array of
locations with one or more active test compounds that produced test
compound induced changes during the primary screen, and optionally
with one or more control compounds; and
[0100] F) detecting active test compound induced changes in the
fluorescent signals from the first fluorescent reporter molecule on
the at least second array of locations, the second fluorescent
reporter molecule on the at least third array of locations, the
third fluorescent reporter molecule on the at least fourth array of
locations, and/or the fourth fluorescent reporter molecule on the
at least fifth array of locations, wherein an active test compound
induced change in the fluorescent signals from the first
fluorescent reporter molecule on the at least second array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the first
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the second
fluorescent reporter molecule on the at least third array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the second
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the third
fluorescent reporter molecule on the at least fourth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the third
fluorescent reporter molecule, and wherein an active test compound
induced change in the fluorescent signals from the fourth
fluorescent reporter molecule on the at least fifth array of
locations indicates an effect of the one or more active test
compounds on the cellular event reported on by the fourth
fluorescent reporter molecule.
[0101] Similar deconvolving methods can be designed for any number
of reporter sets with any number of fluorescent reporter molecules
in a reporter set, based on appropriate selection of fluorescent
reporter molecules and filter sets, as described above. [0102] b.
All secondary screens carried out on same array of locations as the
primary screen: In this embodiment, a second round of screening on
the same array is conducted, thus necessitating that one be able to
distinguish the results of the primary screen from the results of
the secondary screen. For example, if the primary screen utilized
an array with cells that had been contacted with fluorescent
reporter molecules comprising antibodies A, B, and C, where A was
produced in sheep, B was produced in rabbits, and C was produced in
mice, then the secondary screen could involve contacting the same
cells with three new fluorescent reporter molecules comprising
antibodies D, E, and F, where D specifically recognized sheep
antibodies, E specifically recognized rabbit antibodies, and F
specifically recognized mouse antibodies, and wherein D, E, and F
were spectrally distinguishable. Alternatively, some type of
specific tertiary staining that would yield spectrally
distinguishable fluorescent reporter molecules D, E, and F can be
used. Thus, on a single array, one could carry out both the primary
and the secondary screens, further increasing the speed and
efficiency of the method.
[0103] For example, one embodiment of complete deconvolving using
all secondary screens carried out on the same array of locations as
the primary screen, when the cells possess a single reporter set of
two fluorescent reporter molecules, comprises:
[0104] A) contacting the cells in only positive locations on the at
least first array of locations in which a test compound induced
change was detected, and optionally control locations, with at
least a third fluorescent reporter molecule and a fourth
fluorescent reporter molecule, wherein the third fluorescent
reporter and the fourth fluorescent molecule are optically
distinguishable from each other and from the first fluorescent
reporter molecule and the second fluorescent reporter molecule, and
wherein the third fluorescent reporter molecule reports on the same
cellular event as the first fluorescent reporter molecule, and
wherein the fourth fluorescent reporter molecule reports on the
same cellular event as the second fluorescent reporter
molecule;
[0105] B) imaging the positive locations on the at least first
array of locations, and optionally control locations, in high
content mode to obtain fluorescent signals from the third
fluorescent reporter molecule and the fourth fluorescent reporter
molecule; and
[0106] C) detecting active test compound induced changes in the
fluorescent signals from the third fluorescent reporter molecule
and/or the fluorescent signals from the fourth fluorescent reporter
molecule, wherein an active test compound induced change in the
fluorescent signals from the third fluorescent reporter molecule
indicates an effect of the one or more active test compounds on the
cellular event reported on by the first fluorescent reporter
molecule, and wherein an active test compound induced change in the
fluorescent signals from the at least fourth fluorescent reporter
molecule indicates an effect of the one or more active test
compounds on the cellular event reported on by the second
fluorescent reporter molecule.
[0107] If the cells possess a single reporter set of three
different fluorescent reporter molecules, one embodiment of
complete deconvolution on the same array of locations as the
primary screen comprises:
[0108] A) contacting the cells in only positive locations on the at
least first array of locations in which a test compound induced
change was detected, and optionally control locations, with at
least a fourth fluorescent reporter molecule, a fifth fluorescent
reporter molecule, and a sixth fluorescent reporter molecule,
wherein the fourth fluorescent reporter molecule, the fifth
fluorescent reporter molecule, and the sixth fluorescent reporter
molecule are optically distinguishable from each other and from the
fluorescent reporter molecules in the first reporter set, and
wherein the fourth fluorescent reporter molecule reports on the
same cellular event as the first fluorescent reporter molecule,
wherein the fifth fluorescent reporter molecule reports on the same
cellular event as the second fluorescent reporter molecule, and
wherein the sixth fluorescent reporter molecule reports on the same
cellular event as the third fluorescent reporter molecule;
[0109] B) imaging the positive locations on the at least first
array of locations, and optionally control locations, in high
content mode to obtain fluorescent signals from the fourth
fluorescent reporter molecule, the fifth fluorescent reporter
molecule, and the sixth fluorescent reporter molecule; and
[0110] C) detecting active test compound induced changes in the
fluorescent signals from the fourth fluorescent reporter molecule,
the fluorescent signals from the fifth fluorescent reporter
molecule, and/or the fluorescent signals from the sixth fluorescent
reporter molecule, wherein an active test compound induced change
in the fluorescent signals from the fourth fluorescent reporter
molecule indicates an effect of the one or more active test
compounds on the cellular event reported on by the first
fluorescent reporter molecule, wherein an active test compound
induced change in the fluorescent signals from the fifth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
second fluorescent reporter molecule, and wherein an active test
compound induced change in the fluorescent signals from the sixth
fluorescent reporter molecule indicates an effect of the one or
more active test compounds on the cellular event reported on by the
third fluorescent reporter molecule.
[0111] If the cells possess two reporter sets of two different
fluorescent reporter molecules each, one embodiment of complete
deconvolution on the same array of locations as the primary screen
comprises:
[0112] A) contacting the cells in only positive locations on the at
least first array of locations in which a test compound induced
change was detected, and optionally control locations, with at
least a fifth fluorescent reporter molecule, a sixth fluorescent
reporter molecule, a seventh fluorescent reporter molecule, and an
eighth fluorescent reporter molecule, wherein the fifth fluorescent
reporter molecule, the sixth fluorescent molecule, the seventh
fluorescent molecule, and the eighth fluorescent molecule are
optically distinguishable from each other and from the fluorescent
reporter molecules in the first reporter set and the second
reporter set, and wherein the fifth fluorescent reporter molecule
reports on the same cellular event as the first fluorescent
reporter molecule, the sixth fluorescent molecule reports on the
same cellular event as the second fluorescent molecule, the seventh
fluorescent molecule reports on the same cellular event as the
third fluorescent molecule, and wherein the eighth fluorescent
reporter molecule reports on the same cellular event as the fourth
fluorescent reporter molecule;
[0113] B) imaging the positive locations on the at least first
array of locations, and optionally control locations, in high
content mode to obtain fluorescent signals from the fifth
fluorescent reporter molecule, the sixth fluorescent reporter
molecule, the seventh fluorescent reporter molecule, and the eighth
fluorescent reporter molecule; and
[0114] C) detecting active test compound induced changes in the
fluorescent signals from the fifth fluorescent reporter molecule,
the sixth fluorescent reporter molecule, the seventh fluorescent
reporter molecule, and/or the eighth fluorescent reporter molecule,
wherein an active test compound induced change in the fluorescent
signals from the fifth fluorescent reporter molecule indicates an
effect of the one or more active test compounds on the cellular
event reported on by the first fluorescent reporter molecule,
wherein an active test compound induced change in the fluorescent
signals from the sixth fluorescent reporter molecule indicates an
effect of the one or more active test compounds on the cellular
event reported on by the second fluorescent reporter molecule,
wherein an active test compound induced change in the fluorescent
signals from the seventh fluorescent reporter molecule indicates an
effect of the one or more active test compounds on the cellular
event reported on by the third fluorescent reporter molecule, and
wherein an active test compound induced change in the fluorescent
signals from the eighth fluorescent reporter molecule indicates an
effect of the one or more active test compounds on the cellular
event reported on by the fourth fluorescent reporter molecule.
[0115] Similar deconvolving methods can be designed for any number
of reporter sets with any number of fluorescent reporter molecules
in a reporter set, based on appropriate selection of fluorescent
reporter molecules and filter sets, as described above. [0116] c.
Some secondary screen carried out on new arrays, some on same array
as for primary screen: Combination of the above methods.
[0117] 2. Partial deconvolution separates the effect of the one or
more test compounds on some of the cellular events reported on by
the fluorescent reporter molecules. Partial deconvolution is
preferred when one is attempting to identify a test compound or
compounds that activate a given specific cellular response, and not
related cellular responses, and data on the response for each
individual fluorescent reporter molecules is not required. For
example, if one wanted to identify a test compound that
specifically activated c-jun translocation from the cytoplasm to
the nucleus, but which did not activate c-fos or Nf-kB
translocation to the nucleus, partial deconvolution (i.e.:
separating out c-jun in a secondary screen, while combining c-fos
and Nf-kB in a single secondary screen) could be used instead of
full deconvolution, to further minimize time and reagent usage, and
to provide information on the specificity of the test compound or
compounds. Alternatively, if the cells screened comprise both a
first and a second reporter set, and the primary screen detects a
test compound that produced a change in the fluorescent signals
only from the first reporter set, than it would be unnecessary to
deconvolve the effects of the test compound on the second reporter
set.
[0118] Thus, in one embodiment, partial deconvolving comprises
deconvolving the effect of the one or more active test compounds on
the cellular events reported on by the fluorescent reporter
molecules in only one of the first reporter set and the at least
second reporter set. As for complete deconvolving, partial
deconvolving can be performed on the same array of locations as the
primary screening, or can be carried out on one or more different
array(s) of locations, or combinations thereof.
[0119] Partial deconvolution can be carried out in multiple ways,
including but not limited to: [0120] a. All secondary screens
carried out on new arrays of locations: At least one of the new
arrays for the secondary screen contains cells that possess more
than one of the fluorescent reporter molecules in a reporter set,
while the other new arrays contain cells that possess only one of
the fluorescent reporter molecules. For example, if the primary
screen utilized cells possessing fluorescent reporter molecules A,
B, C, and D in a single reporter set, then the secondary screen
could be carried out on two new arrays of locations (For example,
Array of locations 1 with cells possessing A and B and Array of
locations 2 with cells possessing C and D; or Array of locations 1
with cells possessing A, B, and C and Array of locations 2 with
cells possessing D) or three new arrays (For example, Array of
locations 1 with cells possessing A, Array of locations 2 with
cells possessing B, and Array of locations 3 with cells possessing
C and D). One of skill in the art will recognize that many such
permutations of secondary screens can be designed.
[0121] FIG. 2 provides one example of this embodiment. Reporter set
1 (R1) consists of fluorescent reporter molecules F1 and F2, while
reporter set 2 (R2) consists of fluorescent reporter molecules F3
and F4. All cells on the array of locations for the primary screen
contain F1, F2, F3, and F4. The primary screen resulted in hits for
R1 at location B2, for R2 at location D3, and for both R1 and R2 at
location G2. In this example, both partial and complete
deconvolution are used. Deconvolution comprises a secondary screen
in which the test compound or compounds used at location B2 in the
primary screen is/are then used to screen a separate array of
locations (a second array of locations), wherein the cells in the
second array comprise F1 and not F2, F3, or F4; a third array of
locations, wherein the cells in the third array comprise F2 and not
F1, F3, or F4; this secondary screen does not require screening for
F3 or F4 (partial deconvolution), since the primary screen was not
a hit relative to R2 at position B2. The test compound or compounds
used at location D3 in the primary screen is/are then used to
screen a separate array of locations (a fourth array of locations),
wherein the cells in the fourth array comprise F3 and not F1, F2,
or F4, and a fifth array of locations, wherein the cells in the
fifth array comprise F4 and not F1, F2, or F3; this secondary
screen does not require screening for F1 or F2 (partial
deconvolution). The test compound or compounds used at location G2
in the primary screen is/are then used to screen the second, third,
fourth, and fifth array of locations (complete deconvolution).
[0122] To deconvolve the entire plate, 4 separate arrays of
locations on a single microplate are used: wells with cells
containing F1 only (2 wells); wells with cells containing F2 only
(2 wells); wells with cells containing F3 only (2 wells); and wells
with cells containing F4 only (2 wells). As will be apparent to one
of skill in the art, the arrangement of the wells that constitute
an "array of locations" in these secondary screens is not critical.
[0123] b. One or more, but not all, of the secondary screens are
carried out on a new array of locations: In this embodiment, one or
more, but not all, of the secondary screens are carried out on the
same array of locations as the primary screen. For example, where
the array of locations for the primary screen includes cells with
fluorescent reporter molecules A, B, and C, a set of secondary
screens could comprise two new arrays of locations, one with cells
possessing only A and one with cells possessing only B, while the
results of the primary screen, compared to the results of the
secondary screens for A and B, are used to determine the effect of
the test compound on C. Thus, a new image is obtained in the
secondary screen only for A and B, not for C. One of skill in the
art will recognize that many such permutations of secondary screens
can be designed. [0124] c. All secondary screens carried out on
same array of locations as the primary screen: Utilizing the same
type of method as described above for complete deconvolution, type
b, one could screen any array of locations comprising cells that
possess fluorescent reporter molecules A, B, and C, where A and B
comprise antibodies made in mice and C comprises an antibody made
in rabbit. The same array would then be used for the secondary
screen, when fluorescent reporter molecule D specific for mouse
antibodies and fluorescent reporter molecule E specific for rabbit
antibodies could also be used, wherein D and E are spectrally
distinguishable. Alternatively, antibodies A and B could be
produced in rabbit and C in mouse and used in the primary screen,
while in the secondary screen antibody D could recognize rabbit
antibodies, while antibody E could recognize mouse antibodies. One
of skill in the art will recognize that many such permutations of
secondary screens can be designed.
[0125] One example of this embodiment is shown in FIG. 3. The
primary screen comprises the use of cells comprising a single
reporter set (R1) of 3 fluorescent reporter molecules (F1-F3).
Primary screening resulted in a hits at locations C10 and E3.
Deconvolution then comprises contacting locations C10 and E3 with a
fourth fluorescent reporter molecule (F4) that reports on the same
cellular event as F1, and a fifth fluorescent reporter molecule
(F5) that reports on the same cellular event as F2, wherein F4 and
F5 are optically distinguishable from each other and from F1-F3. A
hit for F4 in the secondary screen means that the one or more test
compounds effect the cellular event reported on by F1; a hit for F5
in the secondary screen means that the one or more test compounds
effect the cellular event reported on by F2; and no hit for either
F4 or F5 in the secondary screen means that the one or more test
compounds effect the cellular event reported on by F3.
[0126] The use of deconvolution greatly decreases the time and
expense of simultaneously identifying the effect of a given test
compound or compounds on a number of different cellular events.
FIG. 4 is a schematic of potential time savings from using the
methods of the invention, assuming a hit rate of 0.1 to 1.0% of the
compounds tested. Using traditional high content cell-based
screening, conducting 4 separate screens each with one fluorescent
reporter molecule reporting on a cellular event of interest, each
against a 10 microplate compound library requires screening of 40
plates. With an average processing time of one hour per microplate,
the 4 screens require a total processing time of 40 hours.
[0127] In contrast, by using the methods of the invention, this
time can be dramatically reduced. In one non-limiting example, by
conducting a single primary screen using a single reporter set, as
defined herein, containing the same 4 fluorescent reporter
molecules reporting on different cellular events, on a 10
microplate compound library, and then deconvolving the primary
screen on two plates, only 12 plates are required, and thus the
total screening time is 12 hours. This represents a 70% decrease in
the screening time required for a 10 plate compound library.
Greater reductions in time compared to standard high content
cell-based screening can be achieved for larger jobs, or by using
variations of the deconvolution methods disclosed herein.
[0128] Furthermore, the use of fewer plates means the use of less
reagents and drug candidates, which can dramatically decrease the
cost of test compound screening and the use of scarce reagents.
[0129] The cells being screened may also comprise fluorescent
markers that can be used to identify specific cell structures for
various purposes. For example, the cells may be contacted with a
nuclear stain, such as Hoechst 33342, for the purpose of
identifying individual cells. Similarly, fluorescent markers may be
used to create masks of specific cellular regions, in order to
measure fluorescent signals from the fluorescent reporter molecules
in the reporter set(s) within the mask(s). Such fluorescent markers
may in some assays be one of the fluorescent reporter molecules in
a reporter set, or alternatively may be used to add functionality
to the high content cell-based screening assay.
[0130] As used herein, "fluorescence detection device" means a
device capable of carrying out the imaging required to carry out
the invention, including, but not limited to, fluorescence
microscopes; light scanning microscopy systems, including but not
limited to point scanning, spinning disk, confocal, line scanning,
and multi-photon microscopy systems; and epifluorescence
microscopes. In a preferred embodiment, a fluorescence microscope
is used as part of an automated cell screening system, which
further comprises a fluorescence optical system with a stage
adapted for holding cells and a means for moving the stage, a
digital camera, a light source, and a computer for receiving and
processing the digital data from the digital camera, as well as for
storing and displaying the data.
[0131] The methods of the invention may be used to identify
agonists or antagonists of a given cellular event.
[0132] In a further aspect, the present invention provides computer
readable storage media, for automatically carrying out the methods
of the invention on a fluorescence detection device. As used herein
the term "computer readable medium" includes magnetic disks,
optical disks, organic memory, and any other volatile (e.g., Random
Access Memory ("RAM")) or non-volatile (e.g., Read-Only Memory
("ROM")) mass storage system readable by the CPU. The computer
readable medium includes cooperating or interconnected computer
readable medium, which exist exclusively on the processing system
or be distributed among multiple interconnected processing systems
that may be local or remote to the processing system.
[0133] The present invention is not limited to the field of high
content cell-based screening. For example, the same methods can be
used for high throughput screening of cells, as well as screening
of other biological targets, such as tissue sections, cell
extracts, protein extracts, isolated proteins, and isolated nucleic
acids, that comprise the recited reporter sets, wherein the
cellular events are instead "biological events," such as binding to
a specific target, enzymatic activity, protein activation, and gene
expression.
[0134] The present invention is also not limited to the use of
fluorescent reporter molecules, but can also use luminescent,
chemiluminescent, and other types of reporter molecules.
EXAMPLES
1. Reporter Sets and Relevant Image Analysis Methods
[0135] Non-limiting examples of reporter set types, and cellular
events reported on by them: [0136] a. Multiple transcription factor
translocations to a common cell compartment, such as from the
cytoplasm to the nucleus, using transcription factor-fluorescent
protein chimeras, antibodies, or combinations thereof. Fluorescent
signals from this reporter set are measured using any method for
measuring translocation from the cytoplasm to the nucleus, such as
those disclosed in U.S. Pat. No. 5,989,835, WO 98/38490, and WO
00/17643, and those described below. [0137] b. Multiple receptor
internalizations from the cell surface to the cell interior using
receptor-fluorescent protein chimeras, fluorescent ligands for the
receptors, antibody tags, or any combination thereof. Fluorescent
signals from this reporter set would be measured using any method
for measuring translocation from the cell surface to the inside of
the cell, such as those disclosed in WO 00/03246 and described
below. [0138] c. Multiple viral infections using fluorescently
tagged virions, viral-expressed fluorescent protein (such as GFP),
antibodies to viral proteins, or any combination thereof, where
infection is tracked by expression of GFP and its diffusion into
the nucleus, or specific viral proteins translocate into the
nucleus upon viral infection of the cell. Fluorescent signals from
this reporter set would be measured using any method for measuring
translocation from the cytoplasm to the nucleus, such as those
disclosed in U.S. Pat. No. 5,989,835, WO 98/38490, and WO 00/17643,
and those described below. [0139] d. Evaluation of activation of
cell stress pathways. A number of signal transduction factors are
involved in cell stress pathways including kinases such as, JNK,
p38 MAPK, MAPKAP2, Rsk B, and transcription factors ATF-2, ATF-1,
and NFkB, as well as other components. Fluorescent signals from
this reporter set are measured using any method for measuring
translocation from the cytoplasm to the nucleus, such as those
disclosed in U.S. Pat. No. 5,989,835, WO 98/38490, and WO 00/17643,
and those described below. Thus, a screen of a library of compounds
can assess which ones lead to activation of cell stress pathways.
Pathway-specific composite assays would be typically made up of key
sentinel targets of the specific pathway of interest. [0140] e.
Evaluation of activation of different cell stress pathways. There
are multiple cell stress pathways, which could be differentially
assessed. Two basic pathways include p38 MAPK and JNK. The p38 MAPK
pathway can be assessed by using a first reporter set comprising
fluorescent reporters of p38 MAPK, MAPKAP2, and HSP27. The JNK
pathway can be assessed by using a second reporter set comprising
fluorescent reporters of JNK, c-Jun, and ATF-2. In this example,
assaying the p38 MAPK pathway in a first channel and the JNK
pathway in a second channel could assess selectivity of one pathway
over the other. Fluorescent signals from this reporter set are
measured using any method for measuring translocation from the
cytoplasm to the nucleus, such as those disclosed in U.S. Pat. No.
5,989,835, WO 98/38490, and WO 00/17643, and those described below.
[0141] f. Evaluation of activation of mitogenic pathways. A number
of signal transduction factors are involved in mitogenic pathways
leading to cell proliferation including kinases, such as ERK/MAPK,
Rsk 1, Rsk 2, Rsk 3, Mnk 2, and transcription factors, such as
CREB, c-Fos, and srf. Fluorescent signals from this reporter set
are measured using any method for measuring translocation from the
cytoplasm to the nucleus, such as those disclosed in U.S. Pat. No.
5,989,835, WO 98/38490, and WO 00/17643, and those described below.
Thus, a screen on a library of compounds can assess which ones lead
to activation of cell proliferation pathways. [0142] g. Evaluation
of activation of cell stress vs mitogenic pathways. A simultaneous
profiling of a compound library in terms of those that activate
stress pathways vs mitogenic pathways could be accomplished as a
primary screen, using two or more reporter sets as described above.
Fluorescent signals from these reporter sets are measured using any
method for measuring translocation from the cytoplasm to the
nucleus, such as those disclosed in U.S. Pat. No. 5,989,835, WO
98/38490, and WO 00/17643, and those described below. This primary
screen would identify compounds to be deconvolved by stress targets
and/or mitogenic targets, depending on the organization of the
reporter sets. [0143] h. Combined tracking of cell stress,
apoptosis, and viral infection: Fluorescent signals from this
reporter set would be measured using any method for measuring
translocation from the cytoplasm to the nucleus, such as those
disclosed in U.S. Pat. No. 5,989,835, WO 98/38490, and WO 00/17643,
and those described below. Examples of appropriate fluorescent
reporter molecules for this type of reporter set include, but are
not limited to: [0144] 1. Cell stress: NFkB antibody (Zymed, Inc.)
or an engineered Nf-kB fluorescent protein chimera; [0145] 2.
Apoptosis: Caspase 3, 6, or 8 biosensor (See, for example, WO WO
00/26408; Cohen (1997), Biochemical J 326:1-16; Liang et al.
(1997), J. of Molec. Biol. 274:291-302)) [0146] 3. Viral infection:
For example, a fluorescent virion such as adenovirus-GFP, where
infection is tracked by expression of GFP and its diffusion into
the nucleus; alternatively, antibodies against specific viral
proteins that translocate into the nucleus upon viral infection of
the cell can be used. [0147] i. Combined tracking of multiple
organelle states: Fluorescent signals from this reporter set can be
measured using any method for measuring changes in organelle mass,
including but not limited to those disclosed in WO 00/50872 and
WO/00/70342, incorporated by reference herein in their entirety,
and those described below. Examples of appropriate fluorescent
reporter molecules for this type of reporter set include, but are
not limited to: [0148] 1. MITOTRACKER.RTM. green (Molecular Probes
Eugene, Oreg.) to measure mitochondrial mass, [0149] 2.
LYSOTRACKER.TM. green (Molecular Probes Eugene, Oreg.) to measure
lysosomal mass, and [0150] 3. Fluorescent protein targeted to
peroxisomes to measure peroxisomal mass. (See, for example,
WO/00/70342; Amery et al., Biochem J. 336:367-371 (1998); Wiemer et
al., J. Cell Biol. 136:71-80 (1997) for construction of such
targeted proteins). [0151] j. Cytoskeletal integrity: Fluorescent
signals from this reporter set can be measured using any method for
measuring morphology (such as, but not limited to, polymerization,
bundling, etc.) of a cytoplasmic structure, such as those disclosed
in WO 98/38490 and WO 00/17643, and those described below. Examples
of appropriate fluorescent reporter molecules for this type of
reporter set include, but are not limited to: [0152] 1.
Fluorescently labeled tubulin to stain microtubules (WO 98/38490);
and [0153] 2. Fluorescently labeled phalloidin to stain F-actin
(microfilaments) (Molecular Probes Eugene, Oreg.). [0154] k.
Macromolecule translocation from Golgi to cell surface: Fluorescent
signals from this reporter set can be measured using any method for
measuring translocation of a reporter from the cytoplasm to the
cell surface, such as those described in WO 98/38490. A variation
of this assay comprises assaying accumulation in the Golgi of
proteins blocked from secretion (see below). Examples of
appropriate fluorescent reporter molecules for this type of
reporter set include, but are not limited to: [0155] 1. Antibodies
to cytokines, such as interleukins (Available, for example, from
Biogenesis, Ltd. UK) [0156] 2. Antibodies to extracellular
proteases such as collagenases and elastase (Available, for
example, from Biogenesis, Ltd. UK) [0157] 3. Antibodies to growth
factors such as vascular endothelial growth factor (VEGF),
endothelial growth factor (EGF), and nerve growth factor (NGF)
(Available, for example, from Biogenesis, Ltd. UK) [0158] l.
Cytoplasm to membrane translocation: Fluorescent signals from this
reporter set can be measured using any method for measuring
translocation of a reporter from the cytoplasm to the cell
membrane, such as those described in WO 98/38490. Examples of
appropriate fluorescent reporter molecules for this type of
reporter set include, but are not limited to: [0159] 1. GLUT4
antibody or fluorescent protein chimera (reporter of glucose
transport) (FabGennix, Inc.), [0160] 2. Beta-arrestin fluorescent
protein chimera (reporter of GPCR activation) (Barak et al. (1997),
J. Biol. Chem. 272:27497-27500; Daaka et al. (1998), J. Biol. Chem.
273:685-688), or antibodies to beta arrestin, [0161] 3. ARF 6
(reporter of membrane ruffling) antibody or fluorescent protein
chimera, [0162] 4. Fluorescent protein biosensor of profilin
membrane binding (Federov et al. (1994), J. Molec. Biol.
241:480-482; Lanbrechts et al. (1995), Eur. J. Biochem.
230:281-286), and [0163] 5. Rho protein (Self et al. (1995),
Methods in Enzymology 256:3-10; Tanaka et al. (1995), Methods in
Enzymology 256:41-49) [0164] m. Loss of signal from the cell
surface: Fluorescent signals from this reporter set can be measured
using any method for measuring loss of signal from a cell surface,
such as those described in WO 01/35072. Examples of appropriate
fluorescent reporter molecules for this type of reporter set
include, but are not limited to any combination of antibodies to:
external epitopes of amyloid precursor protein (APP) (Available,
for example, from Biogenesis, Ltd. UK), an external loop of any
receptor, N-acetyl glucosamine (NAG) (Amersham; Molecular Probes)
integrins (Available, for example, from Biogenesis, Ltd. UK), MHC
complexes (Available, for example, from Abcam, Ltd. UK).
2. Details of Image Analysis Examples for Primary and Secondary
Screening Assays
[0165] The primary and secondary screens of the instant invention
can comprise any high content cell based screen or combination of
high content screens that a user wants to implement and can utilize
the appropriate combination of fluorescent reporter molecules
required, including but not limited to those described below, and
those described in U.S. Pat. Nos. 5,989,835 and 6,103,479, as well
as published PCT application nos. WO 98/38490, WO 00/03246, WO
00/17643, WO 00/26408, WO 00/50872, WO/00/70342, WO 00/17624,
WO/00/60356, WO/00/70342, WO 01/11340, WO 01/11341, WO 01/35072,
and WO 01/42786.
[0166] By way of non-limiting examples, the following screening and
image analysis methods can be used for various primary and/or
secondary screens according to the methods of the present
invention:
[0167] 1. Cytoplasm to nuclear translocation: (A preferred
embodiment of the method is described in detail in U.S. Pat. No.
5,989,835) A nuclear image is acquired and preferably thresholded
to create a nuclear mask. A cytoplasmic image is created using
either the nuclear image or the fluorescent signals from the
fluorescent reporter molecules in the reporter set. Preferably, a
cytoplasmic mask is created. Translocation of the fluorescent
reporter molecules in an appropriate reporter set(s) between the
nucleus and cytoplasm can then be determined by detecting
fluorescent signals in the nuclear mask and cytoplasmic mask in the
presence and absence of the one or more test compounds.
[0168] 2. Receptor internalization: (A preferred embodiment of the
method is described in detail in WO 00/03246) A nuclear image is
acquired and preferably, thresholded to create a nuclear mask.
Fluorescent signals from the fluorescent reporter molecules in the
reporter set are used to create a fluorescent reporter image, and
preferably a mask is created from the fluorescent reporter image.
Valid internalization of fluorescent reporter molecules in an
appropriate reporter set(s), and the effect of the one or more test
compounds on such receptor internalization, are determined using
the fluorescent reporter mask. A preferred method for assaying
receptor internalization and trafficking is carried out by
detecting fluorescent reporter molecule trafficking through the
endosomal system.
[0169] 3. Changes in Mitochondrial Mass/Potential: (A preferred
embodiment of the method is described in detail in WO 00/50872)
Combining the ability to normalize to mitochondrial mass with a
measure of the membrane potential allows independent assessment of
both parameters. In a non-limiting example, mitochondrial membrane
potential is measured by labeling mitochondria with a combination
of fluorescent reporter molecules, such as MITOTRACKER.RTM. Green
FM and MITOTRACKER.RTM. Red (Molecular Probes, Inc). In this
example, MITOTRACKER.RTM. Red labeling is proportional to both mass
and membrane potential. MITOTRACKER.RTM. Green FM labeling is
proportional to mass. The ratio of MITOTRACKER.RTM. Red signal to
the MITOTRACKER.RTM. Green FM signal provides a measure of
mitochondrial membrane potential (Poot and Pierce, 1999). This
ratio normalizes the mitochondrial mass with respect to the
MITOTRACKER.RTM. Red signal.
[0170] 4. Cytoskeletal integrity: (Preferred embodiments of the
method are described in detail in WO 98/38490, WO 00/17643, and WO
00/50872.) In a non-limiting example, quantitation of f-actin
content and assembly state is accomplished by measuring the
intensity of phalloidin staining (or other fluorescent reporter
specific for actin) around a nuclear mask, and quantitation of
microtubule polymerization state is preferably accomplished by
measuring the intensity of .beta.-tubulin staining (or other
fluorescent reporter specific for tubulin) around a nuclear
mask.
[0171] 5. Changes in organelle mass: (A preferred embodiment of the
method is described in detail in WO/00/70342.) In a non-limiting
example, a whole cell mask is created using an appropriate cell
indicator marker such as phalloidin or chloromethylfluorescein
diacetate (CMFDA), and adaptively thresholding the image obtained.
The whole cell mask generated can then be applied to the image
obtained for the fluorescent reporter molecules in an appropriate
reporter set specific to the organelle of interest to obtain a
measurement for abundance/mass of the organelle, based on the
integrated fluorescence intensity.
[0172] 6. Cytoplasm to cell membrane translocation: (A preferred
embodiment of the method is described in detail in WO 98/38490.) In
a non-limiting example, masks are created of the plasma membrane
and the cytoplasm. These masks are used to mask the image of the
fluorescent reporter molecules in an appropriate reporter set(s)
that translocate from the cytoplasm to the cell surface. The
integrated brightness per unit area under each mask is used to form
a translocation quotient by dividing the plasma membrane integrated
brightness/area by the cytoplasmic integrated brightness/area. By
comparing the translocation quotient values from control and
experimental wells, the percent translocation is calculated for
each test compound or compounds.
[0173] 7. Translocation between the endoplasmic reticulum and the
Golgi: (A preferred embodiment of the method is described in detail
in WO 98/38490.) In a non-limiting example, masks of the
endoplasmic reticulum and the Golgi domains are created and used to
mask the image of the fluorescent reporter molecules in an
appropriate reporter set(s) whose activation is measured by
translocation between the endoplasmic reticulum and the Golgi. The
integrated brightness per unit area under each mask is used to form
a translocation quotient by dividing the endoplasmic reticulum
integrated brightness/area by the Golgi integrated brightness/area.
By comparing the translocation quotient values from control and
experimental wells, the percent translocation is calculated for
each test compound or compounds.
[0174] Alternatively, reagents that block protein secretion and
cause accumulation of the proteins in the Golgi (BioSource,
Camarillo, Calif.) can be used to block transport of intracellular
cytokines. Thus one can assay for compounds that stimulate cytokine
production by using the reagent to cause accumulation of the
cytokines in the Golgi, where they can be visualized using the
above methods.
[0175] 8. Cell Spreading: (A preferred embodiment of the method is
described in detail in WO 01/42786.) In a non-limiting example, the
fluorescent reporter molecules of an appropriate reporter set are
used to create a cytoplasmic image of the cell, which is used to
create a cytoplasmic mask. Various cell-based morphological
features can then be automatically calculated, including cell area,
cell perimeter, cell shape, cell aggregate intensity, and cell
average intensity. These morphological features provide a measure
of the effect of the test stimulus on cell spreading.
[0176] 9. Neurite outgrowth (or other cellular outgrowth): (A
preferred embodiment of the method is described in detail in WO
01/11340.) In a non-limiting example, a nuclear mask is created as
described above, and the degree of neurite outgrowth (or other
cellular outgrowth) is identified by classifying the fluorescent
images from the fluorescent reporter molecules in an appropriate
reporter set(s) into two groups: the cell body; and neurites (or
outgrowths) All of the outgrowths and processes emerging from the
cell body are classified as neurites (outgrowths). The results
obtained from applying the present method allow the user to define
and classify the neurites (outgrowths) according to their own
classification guidelines. One can identify the characteristics
and/or degree of outgrowth in the well and for individual cells and
cell clusters.
[0177] 10. Cell State Analysis: (A preferred embodiment of the
method is described in detail in WO 01/35072.) In a non-limiting
example, all the cells in the population are identified by, for
example, a nuclear stain, and the fluorescent report molecules in
an appropriate reporter set(s) are specific for a particular
physiological state of the cells, and thus an appropriate reporter
set reports on multiple different physiological states. The states
can be mutually exclusive (e.g. the cell is alive or dead) or the
cell can be in several different states at the same time. For
example, in a brain cell population, different fluorescent reporter
molecules in the reporter set could assess whether the cell (1) is
a neuron, (2) is alive, and (3) expresses certain neuron-specific
proteins. Cross correlation analysis between the different states
provides a more complete characterization of the different states
of the individual cells in a population. In a non-limiting example,
a nuclear stain is used to identify all cells, and the fluorescent
reporter molecules in an a first reporter set are specific for
either live or dead cells The basis of the screen is that when
cells die (or are dying) their membranes become leaky and permeable
to large macromolecules. This allows the entry of
membrane-impermeant markers, including nucleic-acid dyes such as
propidium iodide, and the loss of soluble cytoplasmic markers, such
as esterases. Cytoplasmic esterase activity in live cells causes
the retention of and converts the non-fluorescent live-cell
indicator chloromethyl fluorescein diacetate (CMFDA) (Molecular
Probes, Inc.) into a fluorescent product. Dead cells can be
identified by the presence of nuclear propidium iodide ("PI")
(Molecular Probes, Inc.) fluorescence in the red channel, and live
cells can be identified by cytoplasmic CMFDA fluorescence in the
green channel.
3. Specific Examples
[0178] In this example, two reporter sets were used, each
containing two fluorescent reporter molecules. The first reporter
set consisted of ALEXA FLUOR.RTM. 488 conjugated secondary
antibodies (Molecular Probes, Inc.), which both emit fluorescence
detectable in the green channel. These secondary antibodies were
used to bind to primary antibodies against extracellular (signal)
regulated kinase (ERK) (Cell Signaling Technologies, Inc.) and
Nf-kB (Zymed, Inc.). The second reporter set consisted of ALEXA
FLUOR.RTM. 568 conjugated secondary antibodies (Molecular Probes,
Inc.) which both emit fluorescence detectable in the red channel.
These secondary antibodies were used to bind to primary antibodies
against c-jun and p38.
[0179] In this experiment, the transcription factors under
investigation translocate from the cytoplasm to the nucleus upon
activation. Therefore, the fluorescent reporter molecules, which
indirectly bind to the transcription factors, can be used to
monitor the distribution of the transcription factors within the
cell. However, each reporter reports on a different cellular event
(i.e.: ERK translocation, Nf-kB translocation, c-jun translocation,
and p38 translocation).
[0180] Swiss 3T3 cells in EMEM culture medium were plated in 96
well plates, at a plating density of 3,500 cells per well, and
allowed to incubate overnight. Various columns of wells in the
microplate were treated with TNF (known to activate NFkB), PMA
(known to activate ERK and p38), anisomysin (known to activate p38
and c-jun), or were left untreated, and the cells were incubated at
37.degree. C. in 5% CO.sub.2 for 30 minutes. Cells were washed with
37.degree. C. PBS (200 .mu.l per well), which was then aspirated
prior to adding 200 .mu.l of 37.degree. C. 3.7% formaldehyde in
PBS. The cells were incubated at room temperature for 30 minutes,
followed by washing twice with permeabilization buffer (0.1% Triton
X-100 in PBS), leaving the second wash on for 15 minutes. The cells
were then washed once with 200 .mu.l of PBS at room temperature,
the PBS was removed, and a solution of primary antibodies (as
listed in Table 1) was added in a volume of 50 .mu.l. The antibody
incubation was carried out at room temperature for one hour,
followed by 2 washes with 0.1% Tween 20 in PBS, followed by
incubation with the secondary antibodies, as listed in Table 1. The
secondary antibodies were added to obtain a final dilution of
1:100, plus Hoechst dye (1:2000) to label nuclei and thus identify
the cells. This incubation proceeded for one hour, followed by two
washes with each of Tween 20 and PBS. The plate was then sealed and
stored at 4.degree. C. until scanning on the ARRAYSCAN.RTM. HCS
system (Cellomics, Inc. Pittsburgh, Pa.). TABLE-US-00001 TABLE 1
Fluorescent reporter molecule Target Channel 1.degree. antibody
2.degree. antibody Marker nucleus 1 - blue -- -- Hoechst ERK 2 -
green Rabbit anti-ERK (p) Goat anti-rabbit ALEXA FLUOR .RTM. 488
NFkB 2 - green Rabbit Goat anti-rabbit anti-NFkB (p) ALEXA FLUOR
.RTM. 488 cJUN 3 - red Mouse Goat anti-mouse anti-cJUN (p) ALEXA
FLUOR .RTM. 568 P38HOG 3 - red Mouse anti-p38 (p) Goat anti-mouse
ALEXA FLUOR .RTM. 568
[0181] No deconvolution was necessary, as the known effects of
compounds were being tested. The results in the figures thus
represent the data generated from the primary screen.
Expected Results
[0182] The various possible outcomes of such a screen are given in
Table 2, along with an interpretation of results and follow-up
steps. Average hit rates in most good high content cell based
screens do not exceed 0.1% to 1.0% of compounds screened, and
therefore most of the wells will be negative with no requirement
for secondary screening. TABLE-US-00002 TABLE 2 Follow up outcome
Potential scenarios (Deconvolution) % events No All negative none
96-99 translocation Green trans 1. ERK pos/NFkB neg/cJUN & p38
neg Matrix test 1-2 2. NFkB pos/ERK neg/cJUN & p38 neg ERK/NFkB
3. NFkB &ERK pos/cJUN & p38 neg Red trans 1. cJUN pos/p38
neg/ERK & NFkB neg Matrix test 1-2 2. p38 pos/cJUN neg/ERK
& NFkB neg p38/cJUN 3. p38 & cJUN pos/ERK & NFkB neg
Green/Red 1. ALL pos Matrix test both 1-2 trans 2. ERK pos/NFkB
neg/cJUN & p38 pos ERK/NFkB 3. ERK neg/NFkB pos/cJUN & p38
pos p38/cJUN 4. ALL OTHER COMBINATIONs or consider them to be too
nonspecific
Results:
[0183] Below are two summary graphs of the translocation observed
for the cells exposed to various stimulators FIG. 5 depicts
measurements from the green channel and clearly shows that both
NFkB and ERK specific translocations can be observed (increase in
differences between cytoplasm and nuclear localization) in response
to TNF and PMA, while anisomysin has no effect on translocation in
the green channel over negative controls. FIG. 6 summarizes the
data in the red channel, and shows an increase in translocation for
p38 and c-jun in response to PMA and anisomysin but not TNF. Thus,
these results clearly demonstrate the feasibility of the methods of
the present invention.
* * * * *